Skip to main content
OpenTrials
Completed

NCT Number: NCT07183735

A Crossover Trial to Examine the Efficacy of a Powder to Improve Sleep Quality and Performance

This is a randomized, placebo-controlled crossover study to assess the efficacy of BEAM's Dream Powder in improving sleep health among 40 adults. Participants will use a placebo for 2 weeks, followed by the test product for 4 weeks, with sleep data collected via questionnaires and a Fitbit sleep tracker.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • 18+ years old
  • Self-reported issues with sleeping, falling asleep, or staying asleep.
  • Willing to discontinue any supplements, medications, herbal remedies, or melatonin products used to assist with sleep for the study duration.
  • Willing to avoid introducing any other supplements, medications, herbal remedies, or melatonin products used to assist with sleep for the duration of this trial.
  • Willing to maintain their standard sleep pattern and activity level for the duration of the study.
  • Be generally healthy and not live with any uncontrolled chronic disease.

Exclusion criteria

  • Diagnosed with any chronic sleep condition, including but not limited to insomnia, narcolepsy, or sleep apnea.
  • Women who are pregnant, breastfeeding, or trying to conceive.
  • Anyone unwilling or unable to follow the study protocol.
  • Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Is currently undergoing, or planning to undergo, any significant medical procedures during the study period.
  • Has undergone any surgeries or invasive treatments in the last six months.
  • A history of severe allergic reactions, including but not limited to any of the product's ingredients.
  • Anyone with a nut allergy.
  • Heavy drinkers. A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week.
  • Anyone who uses illicit drugs.
  • Use any prescription medication, over-the-counter, or herbal remedies that can affect sleep.
  • Have a job that involves working the third or night shifts.

Treatment and study plan

BEAM Dream Powder

Dietary Supplement

A powdered sleep supplement. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 3-6.

Placebo Control

Dietary Supplement

A powdered placebo product. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 1-2.

Primary outcomes

  1. Change in sleep quality as measured by the Sleep Quality Scale (SQS)

    Time frame: Baseline, Week 2, Week 4, Week 6

    Sleep quality will be assessed using the self-reported Sleep Quality Scale (SQS), a validated questionnaire evaluating subjective sleep quality.

  2. Change in sleep quantity and architecture as measured by sleep tracker

    Time frame: Baseline, Week 2, Week 4, Week 6

    Objective sleep metrics (e.g., time to fall asleep, deep sleep, REM sleep, sleep transitions, sleep duration, and frequency of waking) will be collected using a sleep tracking device.

Secondary outcomes

  1. Change in perceived restfulness as measured by self-reported questionnaire

    Time frame: Baseline, Week 2, Week 4, Week 6

    Participants will report perceived restfulness levels to assess subjective recovery and rest post-intervention.

  2. Change in overall energy levels as measured by self-reported questionnaire

    Time frame: Baseline, Week 2, Week 4, Week 6

    Participants will rate their energy levels using a structured questionnaire.

  3. Change in emotional well-being as measured by self-reported questionnaire

    Time frame: Baseline, Week 2, Week 4, Week 6

    Emotional well-being will be assessed using a validated self-report measure.

  4. Change in cognitive function as measured by self-reported questionnaire

    Time frame: Baseline, Week 2, Week 4, Week 6

    Cognitive function will be assessed through a participant questionnaire evaluating attention, memory, and mental clarity.

  5. Change in dietary behavior (e.g., hunger levels) as measured by self-reported questionnaire

    Time frame: Baseline, Week 2, Week 4, Week 6

    Participants will report perceived hunger levels and related dietary behavior using a structured questionnaire.

Sponsors and collaborators

Lead sponsor

Beam

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Sep 19, 2025
Registry last updated
Sep 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.